C12N 2500/40
Nucleotides, nucleosides or bases
C12N2500/40 (Nucleotides, nucleosides or bases) appears on 143 US grants and 270 published applications in this corpus.
Search patents in C12N- Granted patents
- 143
- Published applications
- 270
- Assignees
- 203
- Inventors
- 588
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 1 | 0 |
| 1999 | 4 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 1 |
| 2002 | 2 | 6 |
| 2003 | 4 | 7 |
| 2004 | 2 | 3 |
| 2005 | 6 | 8 |
| 2006 | 1 | 4 |
| 2007 | 1 | 6 |
| 2008 | 3 | 3 |
| 2009 | 1 | 7 |
| 2010 | 5 | 6 |
| 2011 | 5 | 16 |
| 2012 | 2 | 5 |
| 2013 | 3 | 8 |
| 2014 | 5 | 8 |
| 2015 | 1 | 13 |
| 2016 | 5 | 14 |
| 2017 | 7 | 12 |
| 2018 | 6 | 13 |
| 2019 | 7 | 16 |
| 2020 | 7 | 13 |
| 2021 | 6 | 18 |
| 2022 | 12 | 20 |
| 2023 | 9 | 23 |
| 2024 | 2 | 15 |
| 2025 | 14 | 10 |
| 2026 | 6 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for increasing T cell function15 Sep 2026US 12,734,150 B2Ludwig Institute for Cancer Research
- Automated method for preparing retinal pigment epithelium cells5 May 2026US 12,618,045 B2Centre D'Etude Des Cellules Souches (Cecs)
- Xeno-free and transgene-free reprograming of mesenchymal stem cells toward neural progenitor cells17 Mar 2026US 12,577,532 B2Institute for Scientific Research and Technology Services (Indicasat)
- Methods for differentiating dopaminergic neurons from stem cells3 Mar 2026US 12,565,639 B2Aspen Neuroscience, Inc.
- Methods and products for transfecting cells24 Feb 2026US 12,559,772 B2Factor Bioscience Inc.
- Xeno-free and transgene-free reprograming of mesenchymal stem cells toward neural progenitor cells1 Oct 2026US 2026/0297516 A1
- Programming B Cells to Produce IL-27 to Treat Inflammatory Diseases10 Sep 2026US 2026/0263596 A1Board of Regents, The University of Texas System
- Methods for overcoming glutamine deprivation during mammalian cell culture27 Aug 2026US 2026/0250628 A1Biogen MA Inc.
- Method and composition for reprogramming cells23 Jul 2026US 2026/0209691 A1Athergen, Inc.
- Use of conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord for inducing, stimulating and promoting hair growth and regeneration9 Jul 2026US 2026/0191766 A1Cellresearch Corporation Pte. Ltd.
Most cited
By later US patents
- Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins500US 5,122,469 AGenentech, Inc. · 1992
- Serum-free, synthetic, completely chemically defined tissue culture media450US 4,657,866 A1987
- In-vitro method for producing antigen-specific human monoclonal antibodies378US 5,229,275 AAkzo N. V. · 1993
- Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture209US 6,800,480 B1Geron Corporation · 2004
- Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid139US 7,442,548 B2Wisconsin Alumni Research Foundation · 2008